Nathan Dormer

Jan 7, 2025 | pharmaceuticalonline.com | Akihisa Nonoyama |David Friend |Cory Berkland |Nathan Dormer

Webinar: Quantifying and Assessing Cleaning & Disinfection Residues: A Case StudyThis presentation reviews the impact of cleaning and disinfectant residues in ATMP cGMP manufacturing, focusing on their risks and management. It addresses how Annex 1 revisions highlight the need for better residue control, offers methods to quantify residues beyond visual inspection, and discusses designing effective cleaning regimes. Click here to learn more.

Jul 31, 2024 | outsourcedpharma.com | Louis Garguilo |Ulrich Lein |Stefani Godoy Herrera |Nathan Dormer

What's your development and manufacturing outsourcing strategy based on? Do you have the right contracts and external relationships in place to successfully implement that strategy? Are there new models for sponsor-CDMO partnerships? Join Outsourced Pharma Live on August 13th as our panel of professionals will provide personal analysis and ideas for determining how you might best conduct your development and manufacturing activities, outsourcing business models, and external relationships.

Jun 13, 2024 | outsourcedpharma.com | Nathan Dormer |Louis Garguilo

By Nathan Dormer, PhD, Director of Drug Development Controlled or modified release indicates that the entire drug release is not immediate (i.e., 85% in 30 minutes or less). Drug release profiles can be immediate, delayed immediate, sustained, or delayed sustained; dispersed formats also exist that can achieve each profile. Even within sustained release, diffusion- and erosion-based systems can approximate asymptotic- and linear/zero-order-profiles, respectively.

Jun 7, 2024 | outsourcedpharma.com | Louis Garguilo |EMA Updates Guidance |Tim Sandle |Nathan Dormer

Webinar: You Had Me at Flow: The Shift from Batch to Continuous A clear increase in continuous flow processes has emerged over the past decade thanks to the commercialization of preparative flow reactor units. This need for continuous flow manufacturing of active pharmaceutical ingredients and fine chemicals continues to grow as it offers important advantages over traditional batch manufacturing in terms of quality, safety, and sustainability of the overall process. Click here to learn more.

Oct 11, 2023 | outsourcedpharma.com | Peter Alexander |Phillip Ramsey |Nathan Dormer |Tim Rich |Louis Garguilo

Accelerated development schedules, quicker pathways to approvals, emerging technologies and therapies, more outsourcing than ever — often located across the globe. All this presents opportunity, and steepening challenges for your quality and regulatory teams. Join the next Outsourced Pharma Live, where our panel of experts will offer strategies to meet regulatory challenges. This webinar is free to attend thanks to the support of Ajinomoto Bio-Pharma Services.